Fuji Pharma acquires Thai plant

Fuji Pharma has acquired the Olic pharmaceutical manufacturing plant in Ayutthaya province, Thailand, for $53m from DKSH. Charles Toomey, executive vice-president for healthcare business unit at DKSH, said that contract manufacturing is a non-core competency for DKSH and that Fuji has significant manufacturing expertise.
Bangkok Post

Small sales rise and restructuring at DSM

Sales rose 2% to €182m in Q2 2012 for DSM's pharmaceutical business. The company said that business conditions are likely to remain challenging, although it anticipates that it will make further strategic progress. The company also announced a series of restructuring measures including the termination of biosimilar product development by its Percivia joint venture, which will now focus on the existing PER.C6 technology licensing business.
In-pharma Technologist

Boehringer Ingelheim will manufacture gevokizumab for Xoma and Servier at its Biberach, Germany facility, following the transfer of Xoma's berkeley facility to CMC

GEN

Lonza has licenced the induced pluripotent stem cell (iPSC) patent portfolio from iPS Academia Japan

Lonza

AMRI revenues for development/small scale manufacturing fell 8% to $17.9m for H1 2012, while large scale manufacturing rose 4% to $49.0m

AMRI

Cambrex reported Q2 2012 sales of $77.1m, up 14.3% on 2011

Cambrex

CMC acquires Xoma facility

CMC Biologics has acquired Xoma's large-scale biologics manufacturing operations Berkeley, CA. The 3100m² facility includes three 2750L stainless steel bioreactors and two purification suites. CMC expects to begin offering contract manufacturing services from Berkeley when the transaction closes.
GEN

Archimica has been fined £100,000 for its “abysmal management and incompetent” handling of safety procedure at its Sandycroft, UK, site

North Wales Daily Post

Dottikon has entered exclusive talks to acquire Solvias' synthesis and catalysis business unit in Rosental, Switzerland

Dottikon

Rentschle Biotechnologie will develop packaging cell lines containing a novel vector from Hannover Medical School and to use these commercially for the contract manufacturing of gene therapeutics

Hannover Medical School

Ark Therapeutics will supply manufacturing and development services for a European gene therapy company's therapeutic vaccine product

Ark Therapeutics

Custom manufacturing "firm" for Lonza

Lonza reported H1 revenues increasing to CHF1.9bn. The company said demand in its custom manufacturing business was firm, resulting in capacity utilisation above 75% in both chemical and biological plants, as well as a strong project pipeline. Lonza said it had provided a full response to the FDA regarding the 2011 warning letter received at its Hopkinton, MA, plant and that corrective action had been taken. Looking to the future, the company said it has initiated an investment in formulated products.
Reuters

Dalton Pharma Services provided API development and manufacturing for a Dengue fever clinical trial in Singapore

Dalton

Quarterly record sales for SAFC

Sigma-Aldrich's fine chemicals business, SAFC, reported sales of $223m in Q2, with organic growth of 8% over 2011. Company president and ceo Rakesh Sachdev said "We were pleased by the improved performance of our SAFC custom pharma business, which saw solid growth in cGMP manufactured products in second quarter 2012." Sanchev said the division had double digit sales growth for custom-manufactured high-potency compounds to pharma customers which he attributed to customers recognising the company's investment in HPAPI capacity in Wisconsin.
Seeking Alpha

Piramal Healthcare will change its name to Piramal Enterprises following its increase in business activities

Economic Times

Novasep invests in HPAPI manufacturing

Novasep is investing €3m to expand its highly potent API manufacturing capabilities at its Le Mans, France facility. The expansion will allow Novasep to serve the increased demand for manufacturing of novel anti-cancer therapies. The new facility will include the capability to perform cryogenic chemistry at -60C in hastelloy reactors. The company will also add large-scale HPLC chromatography and drying in confined areas to manufacture ADC toxins at commercial scale. The plant expansion is expected to be fully operational by the beginning of 2013.
Novasep

ScinoPharm will manufacture topiramate the API for Vivus' Qsymia, approved by the FDA earlier this week

ScinoPharm

Record Q2 for Albemarle's fine chemicals

Albemarle reported record sales in Q2 2012 at $208.7m up 13% on 2011. The company attributed this to favourable volumes and pricing, partly offset by unfavorable foreign currency impacts.
Seeking Alpha

DSM Pharmaceutical Products will provide process development and cGMP manufacture for one of Recepta Biopharma's lead antibodies in Groningen, The Netherlands

Pharmaceutical Business Review

Israel and Switzerland have requested exclusion from the EU's rules for API importation

In-pharma Technologist